Wide Ranks

AVIR

Atea Pharmaceuticals, Inc.

3.46

Top Statistics
Market Cap 292 M Forward PE -2.07 Revenue Growth 0.00 %
Current Ratio 19.33 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 1.51 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 482 M Total Cash Per Share 5.72 Total Debt 1 M
Total Debt To Equity 0.4000 Current Ratio 19.33 Book Value Per Share 5.43
All Measures
Short Ratio 1503.00 % Message Board Id finmb_252824153 Shares Short Prior Month 2 M
Return On Equity -0.3346 City Boston Uuid 2b022d91-ddb5-3459-9d51-2eb405756366
Previous Close 3.30 First Trade Date Epoch Utc 1 B Book Value 5.43
Beta 0.1700 Total Debt 1 M Volume 187106
Price To Book 0.6373 Fifty Two Week Low 2.88 Total Cash Per Share 5.72
Shares Short Previous Month Date 1 B Target Median Price 6.47 Audit Risk 3
Max Age 86400 Sand P52 Week Change 0.3133 Target Mean Price 6.89
Net Income To Common -174006000 Short Percent Of Float 0.0438 Implied Shares Outstanding 84 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 176310
Average Volume10days 176310 Total Cash 482 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0967 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 8 Regular Market Previous Close 3.30
Target Low Price 6.20 Gmt Off Set Milliseconds -18000000 Fifty Day Average 3.42
Open 3.37 Free Cashflow -17914876 State MA
Dividend Yield 0.00 % Return On Assets -0.1425 Time Zone Short Name EST
Board Risk 9 Trailing Eps -2.07 Day Low 3.37
Address1 225 Franklin Street Shares Outstanding 84 M Compensation Risk 10
Price Hint 4 Target High Price 8.00 Website https://ateapharma.com
52 Week Change 0.1572 Average Volume 191546 Forward Eps -1.53
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 1916.70 %
Is_sp_500 False Regular Market Day High 3.50 Profit Margins 0.00 %
Debt To Equity 0.4000 Fifty Two Week High 4.60 Day High 3.50
Shares Short 2 M Regular Market Open 3.37 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0312
Operating Cashflow -126936000 Currency USD Time Zone Full Name America/New_York
Market Cap 292 M Is_nasdaq_100 False Zip 02110
Quote Type EQUITY Industry Biotechnology Long Name Atea Pharmaceuticals, Inc.
Overall Risk 9 Regular Market Day Low 3.37 Held Percent Institutions 0.7100
Current Price 3.46 Address2 Suite 2100 Enterprise To Ebitda 1.51
Financial Currency USD Current Ratio 19.33 Industry Disp Biotechnology
Number Of Analyst Opinions 3 Country United States Float Shares 64 M
Two Hundred Day Average 3.68 Governance Epoch Date 1 B Enterprise Value -188735808
Forward PE -2.07 Regular Market Volume 187106 Ebitda -124883000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections.

Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.

The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19.

It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV.

Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.